All data in this report are preliminary and subject to change as more information is received.

**Sentinel Provider Surveillance: Influenza-like illness activity**

Week 45 Activity¹ (representing geographic distribution): Sporadic  
Week 45 ILI Activity² (representing intensity of ILI activity): 1 (Minimal)

Provider offices across the US report the amount of influenza-like illness (ILI) they see in their patients each week during regular flu season. These outpatient providers’ offices, which include doctors’ offices, school health services, and community health centers, are called ‘sentinel sites.’ Here we present Massachusetts sentinel site data. Please note that the data represent not only confirmed influenza cases, but also those just with ILI, which may be caused by other viruses. ILI is defined as fever above 100.0°F in addition to either cough or sore throat. ILI is a marker of influenza and is used throughout the regular influenza season to monitor influenza since most people are not tested for influenza. Figure 1 shows that ILI activity remains low and is consistent with activity levels normally seen at this time of year. For more information, see CDC’s influenza surveillance website at [www.cdc.gov/flu/weekly/fluactivitysurv.htm](http://www.cdc.gov/flu/weekly/fluactivitysurv.htm).

---

*Figure 1: Percentage of ILI visits reported by sentinel provider sites*

---

*Influenza-like illness (ILI, defined by fever >100°F and cough and/or sore throat), as reported by Massachusetts sentinel surveillance sites*

¹ CDC activity indicator – indicates how widespread influenza activity level is in the state.  
² CDC ILI activity indicator – more quantitative indicator of the level of ILI activity across the state.
Table 1 below shows a geographical distribution of reported ILI in Massachusetts. Table 1 shows that the Boston Region and Southeast Region are currently reporting mildly increased ILI activity while all other regions remain at low levels of ILI.

**Table 1: Percent ILI reported weekly by Massachusetts sentinel sites**

<table>
<thead>
<tr>
<th>Region</th>
<th>Regional Baseline % ILI*</th>
<th>2015-2016</th>
<th>2014-2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston</td>
<td>0.92</td>
<td>1.04</td>
<td>3</td>
</tr>
<tr>
<td>Central</td>
<td>1.47</td>
<td>0.35</td>
<td>9</td>
</tr>
<tr>
<td>Inner Metro Boston</td>
<td>0.88</td>
<td>0.75</td>
<td>9</td>
</tr>
<tr>
<td>Northeast</td>
<td>0.97</td>
<td>0.76</td>
<td>5</td>
</tr>
<tr>
<td>Outer Metro Boston</td>
<td>1.86</td>
<td>1.56</td>
<td>2</td>
</tr>
<tr>
<td>Southeast</td>
<td>0.78</td>
<td>1.07</td>
<td>1</td>
</tr>
<tr>
<td>West</td>
<td>0.87</td>
<td>0.37</td>
<td>3</td>
</tr>
</tbody>
</table>

*Regional baseline % ILI is calculated weekly using reporting providers’ baseline % ILI estimates.

**Influenza-Associated Hospitalizations**

In 2010, MDPH began to request voluntary reporting of all laboratory-confirmed influenza hospitalizations from hospitals in Massachusetts. As many as 50 acute care hospitals from across the state report these data to MDPH on a weekly basis during flu season. The graph below shows the number of laboratory-confirmed hospitalizations per 1,000 licensed beds represented by reporting hospitals for the current season and two previous seasons.

*Figure 2: Massachusetts laboratory-confirmed influenza hospitalizations*
Laboratory testing for influenza

Laboratories in Massachusetts report all positive influenza laboratory tests to MDPH, including viral culture, polymerase chain reaction (PCR) and rapid influenza diagnostic tests. Because the majority of cases are not tested, the number of 'confirmed' cases does not reflect the overall incidence of influenza; however, this information is essential to track the types of influenza circulating in Massachusetts and can be a useful indicator of the presence and distribution of influenza in the state. Figure 3 illustrates the number of laboratory confirmed cases in Massachusetts by week, shown along with Massachusetts ILI. Table 2 reflects the number of laboratory-confirmed influenza cases by region and influenza type.

Figure 3: Laboratory-confirmed Influenza Cases and Influenza-like Illness
Massachusetts, October 4, 2015 – November 14, 2015

*Influenza cases confirmed via viral culture, PCR or rapid test by specimen collection date.
**Influenza-like illness (ILI, defined as fever>100°F and cough and/or sore throat), as reported by Massachusetts sentinel surveillance sites by CDC week date.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
<td>Untyped</td>
<td>A</td>
<td>B</td>
<td>Untyped</td>
</tr>
<tr>
<td>Region</td>
<td>Week</td>
<td>YTD</td>
<td>Week</td>
<td>YTD</td>
<td>Week</td>
<td>YTD</td>
</tr>
<tr>
<td>Boston</td>
<td>2</td>
<td>36</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Central</td>
<td>2</td>
<td>7</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Inner Metro Boston</td>
<td>0</td>
<td>29</td>
<td>2</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Northeast</td>
<td>0</td>
<td>18</td>
<td>7</td>
<td>21</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Outer Metro Boston</td>
<td>3</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Southeast</td>
<td>2</td>
<td>18</td>
<td>4</td>
<td>14</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>West</td>
<td>4</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>13</td>
<td>127</td>
<td>13</td>
<td>50</td>
<td>2</td>
<td>11</td>
</tr>
</tbody>
</table>

**Testing at the Hinton State Laboratory Institute**

As part of a more comprehensive respiratory surveillance initiative, MDPH’s Bureau of Laboratory Sciences (MDPH-BLS) performs testing to confirm typing and subtyping of circulating influenza viruses followed by testing of influenza-negative samples for the evidence of adenovirus, respiratory syncytial virus (RSV) A/B, parainfluenza virus (PIV) types 1-4, coronavirus (HCoV) HKU1, OC43, NL63, 229E, human metapneumovirus (HMPV), and rhinovirus/enterovirus (RHV/ENT) using a multiplex PCR respiratory viral panel. Samples are submitted by ~60 outpatient healthcare providers (ILINet) and include early influenza positives, as well as specimens and isolates from clinical hospital diagnostic laboratories across Massachusetts. For the 2015-2016 season, Figure 4 and Tables 3 and 4 summarize virologic surveillance testing conducted by MDPH-BLS beginning MMWR week 40 (week ending October 10, 2015). MDPH-BLS performs influenza surveillance testing year round. For the 2015-2016 season to date, two cases of A/H3N2 influenza have been confirmed in 33 cases tested.

**Figure 4: Influenza positive tests reported to CDC by MDPH-BLS, October 4, 2015 – November 14, 2015**
Table 3: Weekly Summary of MDPH-BLS Influenza Surveillance Test Results

<table>
<thead>
<tr>
<th>MMWR Week: (Specimen Collected)</th>
<th>2009 H1N1</th>
<th>seasonal A/H3N2</th>
<th>H3N2v</th>
<th>B Yam</th>
<th>B Vic</th>
<th>No. Flu Pos (%)</th>
<th>Unsat</th>
<th>Total Tested</th>
<th>Total Rec'd</th>
</tr>
</thead>
<tbody>
<tr>
<td>42 (10/18 - 10/24/2015)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0(0%)</td>
<td>1</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>43 (10/25 - 10/31/2015)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0(0%)</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>44 (11/01 – 11/07/2015)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0(0%)</td>
<td>1</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>45 (11/08 – 11/14/2015)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0(0%)</td>
<td>0</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Prior 4 wk Total</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0(0%)</td>
<td>3</td>
<td>19</td>
<td>22</td>
</tr>
<tr>
<td>Cumulative Season total</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2(6%)</td>
<td>3</td>
<td>33</td>
<td>36</td>
</tr>
</tbody>
</table>

All data are subject to change as test results become finalized. The 2015-2016 influenza season began MMWR 40 (10/04-10/10/2015).

Table 4: Weekly Summary of MDPH-BLS non-Influenza Respiratory Surveillance Test Results

<table>
<thead>
<tr>
<th>MMWR Week: (Specimen Collected)</th>
<th>RSV</th>
<th>RHV/ENT</th>
<th>PIV</th>
<th>HMPV</th>
<th>HCV</th>
<th>ADV</th>
<th># Co-Infection</th>
<th>No. Pos (%)</th>
<th>Unsat</th>
<th>Total Tested</th>
<th>Total Rec'd</th>
</tr>
</thead>
<tbody>
<tr>
<td>42 (10/18 – 10/24/2015)</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>3(38%)</td>
<td>0</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>43 (10/25 – 10/31/2015)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0(0%)</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>44 (11/01 – 11/07/2015)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0(0%)</td>
<td>0</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>45 (11/08 – 11/14/2015)</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2(40%)</td>
<td>0</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Prior 4 wk Total</td>
<td>0</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>5(26%)</td>
<td>0</td>
<td>19</td>
<td>19</td>
</tr>
<tr>
<td>Cumulative Season total</td>
<td>0</td>
<td>8</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>10(31%)</td>
<td>0</td>
<td>32</td>
<td>32</td>
</tr>
</tbody>
</table>

All data are subject to change as test results become finalized. The 2015-2016 influenza season began MMWR 40 (10/04-10/10/2015).

At the start of the 2015-2016 season, the first 10 original specimens positive for influenza virus and thereafter 5 representative specimens every two weeks will be sent by MDPH-BLS to a CDC contract laboratory performing National Influenza Virus Surveillance to include antigenic characterization by hemagglutination inhibition (HI), genetic analysis (sequencing) and sensitivity to FDA-approved drugs for identification of resistance. For the 2015-2016 season, two A/H3N2 specimens have been characterized as being antigenically similar to A/Switzerland/9715293/2013-like virus. This virus is covered by the 2015 Southern Hemisphere and the 2015-2016 Northern Hemisphere vaccine formulations.

As samples are received, MDPH-BLS will screen additional samples every two weeks to detect point mutations within the neuraminidase gene of influenza A/H3N2 viruses (E119, R292, and N294) and influenza A/2009 H1N1 viruses (H275 and I223) to assess resistance trends. This information will be reported locally and captured nationally in FluView (http://www.cdc.gov/flu/weekly/). There were three influenza A/2009 H1N1 isolates from MA during the 2009-2010 season with a mutation conferring oseltamivir-resistance (H275Y) and none during the following five seasons.

Table 5: DPH-BLS Influenza Antiviral Resistance Screening: 2015-2016 Season

<table>
<thead>
<tr>
<th>Virus Collection Period: October 4, 2015- ongoing</th>
<th>Oseltamivir</th>
<th>Zanamivir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza A (H3N2)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Samples Tested</td>
<td>Resistant Viruses, Number (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0 (0)</td>
</tr>
<tr>
<td>Influenza A (H1N1)pdm09&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

<sup>1</sup> Samples tested by pyrosequencing at position E119, R292, and N294 within the neuraminidase (NA) gene.
<sup>2</sup> Samples tested by pyrosequencing at position H275 and I223 within the NA gene.

Additional information on national antiviral resistance testing including recommendations for antiviral treatment and chemoprophylaxis of influenza virus infection can be found at [http://www.cdc.gov/flu/weekly/](http://www.cdc.gov/flu/weekly/).